Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer is pursuing. Rather than commercializing vaccines, Novavax aims to turn its research into business development deals, R&D executive Ruxandra Draghia-Akli said.
The post Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease appeared first on MedCity News.
